AU2008266515B2 - Pyrrole derivatives as P2Y12 antagonists - Google Patents

Info

Publication number

AU2008266515B2

AU2008266515B2 AU2008266515A AU2008266515A AU2008266515B2 AU 2008266515 B2 AU2008266515 B2 AU 2008266515B2 AU 2008266515 A AU2008266515 A AU 2008266515A AU 2008266515 A AU2008266515 A AU 2008266515A AU 2008266515 B2 AU2008266515 B2 AU 2008266515B2

Authority

AU

Australia

Prior art keywords

phenyl

alkylene

alkyl

methyl

pyrrol

Prior art date

2007-06-18

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Ceased

Links

• Espacenet
• Global Dossier
• Discuss

• 102100026171 P2Y purinoceptor 12 Human genes 0.000 title abstract description 22
• 101710192338 P2Y purinoceptor 12 Proteins 0.000 title abstract description 20
• 239000005557 antagonist Substances 0.000 title abstract description 10
• 150000003233 pyrroles Chemical class 0.000 title description 2
• 150000001875 compounds Chemical class 0.000 claims abstract description 121
• 238000000034 method Methods 0.000 claims abstract description 30
• 238000011321 prophylaxis Methods 0.000 claims abstract description 15
• 238000002560 therapeutic procedure Methods 0.000 claims abstract description 14
• 239000003814 drug Substances 0.000 claims abstract description 11
• 238000002360 preparation method Methods 0.000 claims abstract description 11
• 208000001435 Thromboembolism Diseases 0.000 claims abstract description 8
• 239000004480 active ingredient Substances 0.000 claims abstract description 7
• 230000008569 process Effects 0.000 claims abstract description 7
• -1 biphenylyl Chemical group 0.000 claims description 163
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 75
• 150000003839 salts Chemical class 0.000 claims description 43
• 229910052736 halogen Inorganic materials 0.000 claims description 35
• 150000002367 halogens Chemical class 0.000 claims description 35
• 229910052757 nitrogen Inorganic materials 0.000 claims description 28
• 125000000623 heterocyclic group Chemical group 0.000 claims description 27
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 26
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 26
• 230000015572 biosynthetic process Effects 0.000 claims description 25
• 208000007536 Thrombosis Diseases 0.000 claims description 24
• 239000000203 mixture Substances 0.000 claims description 23
• 125000004432 carbon atom Chemical group C* 0.000 claims description 20
• LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 claims description 20
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 18
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 17
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
• 238000001356 surgical procedure Methods 0.000 claims description 15
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 14
• 210000003462 vein Anatomy 0.000 claims description 14
• 125000004429 atom Chemical group 0.000 claims description 13
• 208000037803 restenosis Diseases 0.000 claims description 13
• 230000002792 vascular Effects 0.000 claims description 13
• YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 12
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 12
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 12
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 12
• 125000004430 oxygen atom Chemical group O* 0.000 claims description 12
• 125000001544 thienyl group Chemical group 0.000 claims description 12
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 11
• 125000003118 aryl group Chemical group 0.000 claims description 11
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 11
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 11
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 11
• 125000005842 heteroatom Chemical group 0.000 claims description 11
• 239000001301 oxygen Substances 0.000 claims description 11
• 229910052760 oxygen Inorganic materials 0.000 claims description 11
• 230000001575 pathological effect Effects 0.000 claims description 11
• 125000004076 pyridyl group Chemical group 0.000 claims description 11
• KVGZZAHHUNAVKZ-UHFFFAOYSA-N 1,4-Dioxin Chemical compound O1C=COC=C1 KVGZZAHHUNAVKZ-UHFFFAOYSA-N 0.000 claims description 10
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 10
• 239000000460 chlorine Substances 0.000 claims description 10
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
• 229920006395 saturated elastomer Polymers 0.000 claims description 10
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 9
• 229910052801 chlorine Inorganic materials 0.000 claims description 9
• 238000011282 treatment Methods 0.000 claims description 9
• 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 claims description 8
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 8
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 8
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 8
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 8
• KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 8
• FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 8
• 230000003187 abdominal effect Effects 0.000 claims description 8
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 8
• 239000011737 fluorine Substances 0.000 claims description 8
• 229910052731 fluorine Inorganic materials 0.000 claims description 8
• 210000003127 knee Anatomy 0.000 claims description 8
• 210000003141 lower extremity Anatomy 0.000 claims description 8
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 8
• 125000002053 thietanyl group Chemical group 0.000 claims description 8
• 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 claims description 7
• 239000005864 Sulphur Chemical group 0.000 claims description 7
• 125000000217 alkyl group Chemical group 0.000 claims description 7
• JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 7
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 7
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 7
• 125000002541 furyl group Chemical group 0.000 claims description 7
• 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 7
• 208000010378 Pulmonary Embolism Diseases 0.000 claims description 6
• 239000003146 anticoagulant agent Substances 0.000 claims description 6
• 238000004519 manufacturing process Methods 0.000 claims description 6
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 6
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 6
• 206010002388 Angina unstable Diseases 0.000 claims description 5
• 208000006011 Stroke Diseases 0.000 claims description 5
• 208000032109 Transient ischaemic attack Diseases 0.000 claims description 5
• 208000007814 Unstable Angina Diseases 0.000 claims description 5
• 230000001154 acute effect Effects 0.000 claims description 5
• 206010000891 acute myocardial infarction Diseases 0.000 claims description 5
• 238000002399 angioplasty Methods 0.000 claims description 5
• 210000001367 artery Anatomy 0.000 claims description 5
• WURBFLDFSFBTLW-UHFFFAOYSA-N benzil Chemical compound C=1C=CC=CC=1C(=O)C(=O)C1=CC=CC=C1 WURBFLDFSFBTLW-UHFFFAOYSA-N 0.000 claims description 5
• 238000007887 coronary angioplasty Methods 0.000 claims description 5
• 201000004332 intermediate coronary syndrome Diseases 0.000 claims description 5
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 5
• 201000010875 transient cerebral ischemia Diseases 0.000 claims description 5
• SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 claims description 4
• 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 claims description 4
• 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 claims description 4
• JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims description 4
• 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 claims description 4
• FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 claims description 4
• 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 claims description 4
• 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 claims description 4
• 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 claims description 4
• LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 claims description 4
• CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 claims description 4
• CZSRXHJVZUBEGW-UHFFFAOYSA-N 1,2-thiazolidine Chemical compound C1CNSC1 CZSRXHJVZUBEGW-UHFFFAOYSA-N 0.000 claims description 4
• 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 claims description 4
• JIHQDMXYYFUGFV-UHFFFAOYSA-N 1,3,5-triazine Chemical compound C1=NC=NC=N1 JIHQDMXYYFUGFV-UHFFFAOYSA-N 0.000 claims description 4
• 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 claims description 4
• AICIYIDUYNFPRY-UHFFFAOYSA-N 1,3-dihydro-2H-imidazol-2-one Chemical compound O=C1NC=CN1 AICIYIDUYNFPRY-UHFFFAOYSA-N 0.000 claims description 4
• WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims description 4
• ABADUMLIAZCWJD-UHFFFAOYSA-N 1,3-dioxole Chemical compound C1OC=CO1 ABADUMLIAZCWJD-UHFFFAOYSA-N 0.000 claims description 4
• 125000000164 1,3-thiazinyl group Chemical group S1C(N=CC=C1)* 0.000 claims description 4
• OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 claims description 4
• FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 claims description 4
• ZNGWEEUXTBNKFR-UHFFFAOYSA-N 1,4-oxazepane Chemical compound C1CNCCOC1 ZNGWEEUXTBNKFR-UHFFFAOYSA-N 0.000 claims description 4
• 125000005962 1,4-oxazepanyl group Chemical group 0.000 claims description 4
• ITQYXPMCOLYRDK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide 2H-thiopyran Chemical compound C1SC=CC=C1.O=S1(=O)CCNCC1 ITQYXPMCOLYRDK-UHFFFAOYSA-N 0.000 claims description 4
• 125000000183 1,4-thiazinyl group Chemical group S1C(C=NC=C1)* 0.000 claims description 4
• QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 claims description 4
• BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 claims description 4
• POXWDTQUDZUOGP-UHFFFAOYSA-N 1h-1,4-diazepine Chemical compound N1C=CC=NC=C1 POXWDTQUDZUOGP-UHFFFAOYSA-N 0.000 claims description 4
• JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 claims description 4
• IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims description 4
• VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 claims description 4
• RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 claims description 4
• MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 claims description 4
• MSRJJSCOWHWGGX-UHFFFAOYSA-N 2h-1,3-diazepine Chemical compound C1N=CC=CC=N1 MSRJJSCOWHWGGX-UHFFFAOYSA-N 0.000 claims description 4
• KGWNRZLPXLBMPS-UHFFFAOYSA-N 2h-1,3-oxazine Chemical compound C1OC=CC=N1 KGWNRZLPXLBMPS-UHFFFAOYSA-N 0.000 claims description 4
• NTYABNDBNKVWOO-UHFFFAOYSA-N 2h-1,3-thiazine Chemical compound C1SC=CC=N1 NTYABNDBNKVWOO-UHFFFAOYSA-N 0.000 claims description 4
• YHWMFDLNZGIJSD-UHFFFAOYSA-N 2h-1,4-oxazine Chemical compound C1OC=CN=C1 YHWMFDLNZGIJSD-UHFFFAOYSA-N 0.000 claims description 4
• ZAISDHPZTZIFQF-UHFFFAOYSA-N 2h-1,4-thiazine Chemical compound C1SC=CN=C1 ZAISDHPZTZIFQF-UHFFFAOYSA-N 0.000 claims description 4
• BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 claims description 4
• AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 claims description 4
• BWCDLEQTELFBAW-UHFFFAOYSA-N 3h-dioxazole Chemical compound N1OOC=C1 BWCDLEQTELFBAW-UHFFFAOYSA-N 0.000 claims description 4
• XKTYXVDYIKIYJP-UHFFFAOYSA-N 3h-dioxole Chemical compound C1OOC=C1 XKTYXVDYIKIYJP-UHFFFAOYSA-N 0.000 claims description 4
• WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical compound C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 claims description 4
• GUUULVAMQJLDSY-UHFFFAOYSA-N 4,5-dihydro-1,2-thiazole Chemical compound C1CC=NS1 GUUULVAMQJLDSY-UHFFFAOYSA-N 0.000 claims description 4
• NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims description 4
• 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 claims description 4
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 4
• 206010002383 Angina Pectoris Diseases 0.000 claims description 4
• 206010053567 Coagulopathies Diseases 0.000 claims description 4
• YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 claims description 4
• 208000005189 Embolism Diseases 0.000 claims description 4
• 108010056764 Eptifibatide Proteins 0.000 claims description 4
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 4
• WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 claims description 4
• 206010022562 Intermittent claudication Diseases 0.000 claims description 4
• 208000034486 Multi-organ failure Diseases 0.000 claims description 4
• 206010028980 Neoplasm Diseases 0.000 claims description 4
• ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 4
• PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 4
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 4
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 4
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 4
• 206010040070 Septic Shock Diseases 0.000 claims description 4
• DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims description 4
• JZFICWYCTCCINF-UHFFFAOYSA-N Thiadiazin Chemical compound S=C1SC(C)NC(C)N1CCN1C(=S)SC(C)NC1C JZFICWYCTCCINF-UHFFFAOYSA-N 0.000 claims description 4
• ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 4
• 206010047249 Venous thrombosis Diseases 0.000 claims description 4
• 208000036142 Viral infection Diseases 0.000 claims description 4
• 230000002159 abnormal effect Effects 0.000 claims description 4
• 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 claims description 4
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 4
• 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 4
• 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 claims description 4
• 125000005602 azabenzimidazolyl group Chemical group 0.000 claims description 4
• 125000002785 azepinyl group Chemical group 0.000 claims description 4
• 125000002393 azetidinyl group Chemical group 0.000 claims description 4
• 125000004069 aziridinyl group Chemical group 0.000 claims description 4
• 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 claims description 4
• 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims description 4
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 4
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 4
• 125000005512 benztetrazolyl group Chemical group 0.000 claims description 4
• 125000002619 bicyclic group Chemical group 0.000 claims description 4
• 201000011510 cancer Diseases 0.000 claims description 4
• 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 claims description 4
• 125000004623 carbolinyl group Chemical group 0.000 claims description 4
• 125000002843 carboxylic acid group Chemical group 0.000 claims description 4
• 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 claims description 4
• 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 claims description 4
• 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims description 4
• 208000029078 coronary artery disease Diseases 0.000 claims description 4
• 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 claims description 4
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
• 125000002100 cyclohexa-1,3-dienyl group Chemical group [H]C1([*])C([H])=C([H])C([H])=C([H])C1([H])[H] 0.000 claims description 4
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims description 4
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 4
• 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims description 4
• DIXBSCZRIZDQGC-UHFFFAOYSA-N diaziridine Chemical compound C1NN1 DIXBSCZRIZDQGC-UHFFFAOYSA-N 0.000 claims description 4
• PPSZHCXTGRHULJ-UHFFFAOYSA-N dioxazine Chemical compound O1ON=CC=C1 PPSZHCXTGRHULJ-UHFFFAOYSA-N 0.000 claims description 4
• CZKPOZZJODAYPZ-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CNC2=CC=CC=C12 CZKPOZZJODAYPZ-LROMGURASA-N 0.000 claims description 4
• 239000002319 fibrinogen receptor antagonist Substances 0.000 claims description 4
• 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 4
• 125000003838 furazanyl group Chemical group 0.000 claims description 4
• 238000001631 haemodialysis Methods 0.000 claims description 4
• 230000000322 hemodialysis Effects 0.000 claims description 4
• YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 claims description 4
• 125000002632 imidazolidinyl group Chemical group 0.000 claims description 4
• MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 claims description 4
• 125000002636 imidazolinyl group Chemical group 0.000 claims description 4
• 125000002883 imidazolyl group Chemical group 0.000 claims description 4
• 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 4
• 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 4
• 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 claims description 4
• 125000001041 indolyl group Chemical group 0.000 claims description 4
• 208000021156 intermittent vascular claudication Diseases 0.000 claims description 4
• 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 claims description 4
• 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 claims description 4
• 125000005438 isoindazolyl group Chemical group 0.000 claims description 4
• 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims description 4
• 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims description 4
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 4
• ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims description 4
• 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 claims description 4
• 125000005969 isothiazolinyl group Chemical group 0.000 claims description 4
• 125000001786 isothiazolyl group Chemical group 0.000 claims description 4
• CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 4
• 125000003965 isoxazolidinyl group Chemical group 0.000 claims description 4
• 125000003971 isoxazolinyl group Chemical group 0.000 claims description 4
• 125000000842 isoxazolyl group Chemical group 0.000 claims description 4
• 230000007774 longterm Effects 0.000 claims description 4
• 238000012423 maintenance Methods 0.000 claims description 4
• 125000002950 monocyclic group Chemical group 0.000 claims description 4
• 125000002757 morpholinyl group Chemical group 0.000 claims description 4
• 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims description 4
• 208000010125 myocardial infarction Diseases 0.000 claims description 4
• 125000001624 naphthyl group Chemical group 0.000 claims description 4
• 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims description 4
• 125000004930 octahydroisoquinolinyl group Chemical group C1(NCCC2CCCC=C12)* 0.000 claims description 4
• 125000001715 oxadiazolyl group Chemical group 0.000 claims description 4
• OXUZCBDDXOMZAM-UHFFFAOYSA-N oxathiepane Chemical compound C1CCOSCC1 OXUZCBDDXOMZAM-UHFFFAOYSA-N 0.000 claims description 4
• OOFGXDQWDNJDIS-UHFFFAOYSA-N oxathiolane Chemical compound C1COSC1 OOFGXDQWDNJDIS-UHFFFAOYSA-N 0.000 claims description 4
• SJGALSBBFTYSBA-UHFFFAOYSA-N oxaziridine Chemical compound C1NO1 SJGALSBBFTYSBA-UHFFFAOYSA-N 0.000 claims description 4
• 125000000160 oxazolidinyl group Chemical group 0.000 claims description 4
• 125000005968 oxazolinyl group Chemical group 0.000 claims description 4
• 125000002971 oxazolyl group Chemical group 0.000 claims description 4
• AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 claims description 4
• 125000003566 oxetanyl group Chemical group 0.000 claims description 4
• 230000002093 peripheral effect Effects 0.000 claims description 4
• 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 claims description 4
• 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 claims description 4
• 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 claims description 4
• 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 claims description 4
• 125000005954 phenoxathiinyl group Chemical group 0.000 claims description 4
• 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 claims description 4
• 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 4
• 125000004193 piperazinyl group Chemical group 0.000 claims description 4
• 125000003386 piperidinyl group Chemical group 0.000 claims description 4
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
• 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 claims description 4
• 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 4
• 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims description 4
• 125000003373 pyrazinyl group Chemical group 0.000 claims description 4
• USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 claims description 4
• 125000003072 pyrazolidinyl group Chemical group 0.000 claims description 4
• DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 claims description 4
• 125000002755 pyrazolinyl group Chemical group 0.000 claims description 4
• 125000003226 pyrazolyl group Chemical group 0.000 claims description 4
• PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 4
• 125000002098 pyridazinyl group Chemical group 0.000 claims description 4
• UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims description 4
• 125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
• WRHZVMBBRYBTKZ-UHFFFAOYSA-N pyrrole-2-carboxylic acid Chemical compound OC(=O)C1=CC=CN1 WRHZVMBBRYBTKZ-UHFFFAOYSA-N 0.000 claims description 4
• HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 4
• 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 4
• ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 claims description 4
• 125000001422 pyrrolinyl group Chemical group 0.000 claims description 4
• 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 4
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 4
• 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 claims description 4
• 230000036303 septic shock Effects 0.000 claims description 4
• 239000011593 sulfur Substances 0.000 claims description 4
• 229910052717 sulfur Inorganic materials 0.000 claims description 4
• 230000009885 systemic effect Effects 0.000 claims description 4
• 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims description 4
• 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 claims description 4
• 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims description 4
• 125000003507 tetrahydrothiofenyl group Chemical group 0.000 claims description 4
• 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 claims description 4
• 125000003831 tetrazolyl group Chemical group 0.000 claims description 4
• VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims description 4
• 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 claims description 4
• 125000001984 thiazolidinyl group Chemical group 0.000 claims description 4
• CBDKQYKMCICBOF-UHFFFAOYSA-N thiazoline Chemical compound C1CN=CS1 CBDKQYKMCICBOF-UHFFFAOYSA-N 0.000 claims description 4
• 125000002769 thiazolinyl group Chemical group 0.000 claims description 4
• 125000000335 thiazolyl group Chemical group 0.000 claims description 4
• BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims description 4
• 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 4
• 230000002537 thrombolytic effect Effects 0.000 claims description 4
• COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical compound C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 claims description 4
• 238000007891 venous angioplasty Methods 0.000 claims description 4
• 230000009385 viral infection Effects 0.000 claims description 4
• 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 claims description 4
• 125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 claims description 3
• 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 claims description 3
• 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 claims description 3
• 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 claims description 3
• CFRCZLVPCCLZFG-UHFFFAOYSA-N 1,3,4-oxathiazinane 3,3-dioxide Chemical compound O=S1(=O)COCCN1 CFRCZLVPCCLZFG-UHFFFAOYSA-N 0.000 claims description 3
• SNZGLSFRQQENMS-UHFFFAOYSA-N 1-(2-methyl-5-phenyl-1h-pyrrol-3-yl)-2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCN1C1=CC=CC(C(F)(F)F)=C1 SNZGLSFRQQENMS-UHFFFAOYSA-N 0.000 claims description 3
• HOGGFZUTADUSDT-UHFFFAOYSA-N 1-(4-bromo-2-methyl-5-phenyl-1h-pyrrol-3-yl)-2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=C(Br)C=1C(=O)C(=O)N(CC1)CCN1C1=CC=CC(C(F)(F)F)=C1 HOGGFZUTADUSDT-UHFFFAOYSA-N 0.000 claims description 3
• 125000005955 1H-indazolyl group Chemical group 0.000 claims description 3
• 229940123583 Factor Xa inhibitor Drugs 0.000 claims description 3
• 229940122388 Thrombin inhibitor Drugs 0.000 claims description 3
• 125000002197 cyclohepta-2,4,6-trienyl group Chemical group 0.000 claims description 3
• 125000002150 cyclohexa-1,4-dienyl group Chemical group [H]C1=C([H])C([H])(*)C([H])=C([H])C1([H])[H] 0.000 claims description 3
• IGSKHXTUVXSOMB-UHFFFAOYSA-N cyclopropylmethanamine Chemical compound NCC1CC1 IGSKHXTUVXSOMB-UHFFFAOYSA-N 0.000 claims description 3
• 239000003937 drug carrier Substances 0.000 claims description 3
• 229940127215 low-molecular weight heparin Drugs 0.000 claims description 3
• 238000010577 post-coronary angioplasty Methods 0.000 claims description 3
• QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims description 3
• 239000003868 thrombin inhibitor Substances 0.000 claims description 3
• RPAPVILXKDUTCP-ZHACJKMWSA-N (e)-3-[5-methyl-4-[2-oxo-2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]acetyl]-2-phenyl-1h-pyrrol-3-yl]prop-2-enoic acid Chemical compound CC=1NC(C=2C=CC=CC=2)=C(\C=C\C(O)=O)C=1C(=O)C(=O)N(CC1)CCN1C1=CC=CC(C(F)(F)F)=C1 RPAPVILXKDUTCP-ZHACJKMWSA-N 0.000 claims description 2
• PYZOVVQJTLOHDG-FQEVSTJZSA-N 2-[(2s)-4-methyl-3-oxo-7-(4-piperidin-4-ylpiperidine-1-carbonyl)-2,5-dihydro-1h-1,4-benzodiazepin-2-yl]acetic acid Chemical compound O=C([C@H](CC(O)=O)NC1=CC=2)N(C)CC1=CC=2C(=O)N(CC1)CCC1C1CCNCC1 PYZOVVQJTLOHDG-FQEVSTJZSA-N 0.000 claims description 2
• BMXPSHUHHHRCHU-UHFFFAOYSA-N 3,5-dimethyl-4-[2-oxo-2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]acetyl]-1h-pyrrole-2-carboxylic acid Chemical compound N1C(C(O)=O)=C(C)C(C(=O)C(=O)N2CCN(CC2)C=2C=C(C=CC=2)C(F)(F)F)=C1C BMXPSHUHHHRCHU-UHFFFAOYSA-N 0.000 claims description 2
• QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 claims description 2
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 2
• WBNUCLPUOSXSNJ-ZDUSSCGKSA-N Sibrafiban Chemical compound C1CC(OCC(=O)OCC)CCN1C(=O)[C@H](C)NC(=O)C1=CC=C(C(=N)NO)C=C1 WBNUCLPUOSXSNJ-ZDUSSCGKSA-N 0.000 claims description 2
• 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 claims description 2
• 229960000446 abciximab Drugs 0.000 claims description 2
• 229960001138 acetylsalicylic acid Drugs 0.000 claims description 2
• 229940000279 aggrastat Drugs 0.000 claims description 2
• 229960003886 apixaban Drugs 0.000 claims description 2
• 229960000610 enoxaparin Drugs 0.000 claims description 2
• 229960004468 eptifibatide Drugs 0.000 claims description 2
• ZHCINJQZDFCSEL-CYBMUJFWSA-N ethyl (3s)-3-[[4-(4-carbamimidoylanilino)-4-oxobutanoyl]amino]pent-4-ynoate Chemical compound CCOC(=O)C[C@@H](C#C)NC(=O)CCC(=O)NC1=CC=C(C(N)=N)C=C1 ZHCINJQZDFCSEL-CYBMUJFWSA-N 0.000 claims description 2
• VJDOPFARMOLELX-ZDUSSCGKSA-N ethyl 3-[[(3s)-1-(4-carbamimidoylphenyl)-2-oxopyrrolidin-3-yl]carbamoylamino]propanoate Chemical compound O=C1[C@@H](NC(=O)NCCC(=O)OCC)CCN1C1=CC=C(C(N)=N)C=C1 VJDOPFARMOLELX-ZDUSSCGKSA-N 0.000 claims description 2
• KANJSNBRCNMZMV-ABRZTLGGSA-N fondaparinux Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O4)NS(O)(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS(O)(=O)=O)O2)NS(O)(=O)=O)[C@H](C(O)=O)O1 KANJSNBRCNMZMV-ABRZTLGGSA-N 0.000 claims description 2
• 229960001318 fondaparinux Drugs 0.000 claims description 2
• 229960002897 heparin Drugs 0.000 claims description 2
• 229920000669 heparin Polymers 0.000 claims description 2
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
• 229950010501 lotrafiban Drugs 0.000 claims description 2
• 239000003055 low molecular weight heparin Substances 0.000 claims description 2
• IRAXRQFCCSHQDX-WBVHZDCISA-N methyl (2s)-2-(butoxycarbonylamino)-3-[[2-[(5r)-3-(4-carbamimidoylphenyl)-4,5-dihydro-1,2-oxazol-5-yl]acetyl]amino]propanoate Chemical compound O1[C@@H](CC(=O)NC[C@H](NC(=O)OCCCC)C(=O)OC)CC(C=2C=CC(=CC=2)C(N)=N)=N1 IRAXRQFCCSHQDX-WBVHZDCISA-N 0.000 claims description 2
• LCGMUFXDFRKQSI-VAWYXSNFSA-N methyl (e)-3-[5-methyl-4-[2-oxo-2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]acetyl]-2-phenyl-1h-pyrrol-3-yl]prop-2-enoate Chemical compound COC(=O)\C=C\C1=C(C=2C=CC=CC=2)NC(C)=C1C(=O)C(=O)N(CC1)CCN1C1=CC=CC(C(F)(F)F)=C1 LCGMUFXDFRKQSI-VAWYXSNFSA-N 0.000 claims description 2
• MVPQUSQUURLQKF-MCPDASDXSA-E nonasodium;(2s,3s,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3s,4s,5r,6r)-2-carboxylato-4,5-dimethoxy-6-[(2r,3r,4s,5r,6s)-6-methoxy-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxy-4,5-di Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]S(=O)(=O)O[C@@H]1[C@@H](OS([O-])(=O)=O)[C@@H](OC)O[C@H](COS([O-])(=O)=O)[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@@H]2[C@@H]([C@@H](OS([O-])(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](OC)[C@H](O[C@@H]4[C@@H]([C@@H](OC)[C@H](OC)[C@@H](COS([O-])(=O)=O)O4)OC)[C@H](O3)C([O-])=O)OC)[C@@H](COS([O-])(=O)=O)O2)OS([O-])(=O)=O)[C@H](C([O-])=O)O1 MVPQUSQUURLQKF-MCPDASDXSA-E 0.000 claims description 2
• 229950002383 orbofiban Drugs 0.000 claims description 2
• 229950009478 otamixaban Drugs 0.000 claims description 2
• PFGVNLZDWRZPJW-OPAMFIHVSA-N otamixaban Chemical compound C([C@@H](C(=O)OC)[C@@H](C)NC(=O)C=1C=CC(=CC=1)C=1C=C[N+]([O-])=CC=1)C1=CC=CC(C(N)=N)=C1 PFGVNLZDWRZPJW-OPAMFIHVSA-N 0.000 claims description 2
• 229940107685 reopro Drugs 0.000 claims description 2
• 229960001148 rivaroxaban Drugs 0.000 claims description 2
• KGFYHTZWPPHNLQ-AWEZNQCLSA-N rivaroxaban Chemical compound S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2C(COCC2)=O)C1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 claims description 2
• 229950002267 roxifiban Drugs 0.000 claims description 2
• 229950005747 sibrafiban Drugs 0.000 claims description 2
• 229960003425 tirofiban Drugs 0.000 claims description 2
• 229950004893 xemilofiban Drugs 0.000 claims description 2
• ZXIBCJHYVWYIKI-PZJWPPBQSA-N ximelagatran Chemical compound C1([C@@H](NCC(=O)OCC)C(=O)N2[C@@H](CC2)C(=O)NCC=2C=CC(=CC=2)C(\N)=N\O)CCCCC1 ZXIBCJHYVWYIKI-PZJWPPBQSA-N 0.000 claims description 2
• 229960001522 ximelagatran Drugs 0.000 claims description 2
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 24
• KCNKJCHARANTIP-SNAWJCMRSA-N allyl-{4-[3-(4-bromo-phenyl)-benzofuran-6-yloxy]-but-2-enyl}-methyl-amine Chemical group C=1OC2=CC(OC/C=C/CN(CC=C)C)=CC=C2C=1C1=CC=C(Br)C=C1 KCNKJCHARANTIP-SNAWJCMRSA-N 0.000 claims 3
• DWLFYRBVLYKZDN-UHFFFAOYSA-N 1-(2,4-dimethyl-1h-pyrrol-3-yl)-2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethane-1,2-dione Chemical compound CC1=CNC(C)=C1C(=O)C(=O)N1CCN(C=2C=C(C=CC=2)C(F)(F)F)CC1 DWLFYRBVLYKZDN-UHFFFAOYSA-N 0.000 claims 2
• 125000005879 dioxolanyl group Chemical group 0.000 claims 2
• 125000005880 oxathiolanyl group Chemical group 0.000 claims 2
• KVTVRCIQHKUFNP-UHFFFAOYSA-N 1,3,4-oxathiazinane Chemical compound C1COCSN1 KVTVRCIQHKUFNP-UHFFFAOYSA-N 0.000 claims 1
• YJTKNYDMVHNTCO-UHFFFAOYSA-N 1-(2,5-dimethyl-1h-pyrrol-3-yl)-2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethane-1,2-dione Chemical compound N1C(C)=CC(C(=O)C(=O)N2CCN(CC2)C=2C=C(C=CC=2)C(F)(F)F)=C1C YJTKNYDMVHNTCO-UHFFFAOYSA-N 0.000 claims 1
• NSMZPYYQGUTHHX-UHFFFAOYSA-N 1-(2-methyl-5-phenyl-1h-pyrrol-3-yl)-2-(4-phenylpiperazin-1-yl)ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCN1C1=CC=CC=C1 NSMZPYYQGUTHHX-UHFFFAOYSA-N 0.000 claims 1
• JPYAZKXPHUUZFF-UHFFFAOYSA-N 1-(2-methyl-5-phenyl-1h-pyrrol-3-yl)-2-[4-[3-(trifluoromethyl)phenyl]piperidin-1-yl]ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCC1C1=CC=CC(C(F)(F)F)=C1 JPYAZKXPHUUZFF-UHFFFAOYSA-N 0.000 claims 1
• KGDQRWWATJJCBO-UHFFFAOYSA-N 1-(2-methyl-5-phenyl-1h-pyrrol-3-yl)-2-[4-[4-(trifluoromethyl)benzoyl]piperidin-1-yl]ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCC1C(=O)C1=CC=C(C(F)(F)F)C=C1 KGDQRWWATJJCBO-UHFFFAOYSA-N 0.000 claims 1
• PZNPBGZQCALNRA-UHFFFAOYSA-N 1-(2-methyl-5-phenyl-1h-pyrrol-3-yl)-2-[4-[4-(trifluoromethyl)phenyl]piperazin-1-yl]ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCN1C1=CC=C(C(F)(F)F)C=C1 PZNPBGZQCALNRA-UHFFFAOYSA-N 0.000 claims 1
• NRJJSRHQJQEYFQ-UHFFFAOYSA-N 1-(2-methyl-5-pyridin-3-yl-1h-pyrrol-3-yl)-2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethane-1,2-dione Chemical compound CC=1NC(C=2C=NC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCN1C1=CC=CC(C(F)(F)F)=C1 NRJJSRHQJQEYFQ-UHFFFAOYSA-N 0.000 claims 1
• NNDSDCXAKWQCEO-UHFFFAOYSA-N 1-(3,4-difluorophenyl)-4-[2-(2-methyl-5-phenyl-1H-pyrrol-3-yl)ethyl]piperazine Chemical compound FC=1C=C(C=CC1F)N1CCN(CC1)CCC1=C(NC(=C1)C1=CC=CC=C1)C NNDSDCXAKWQCEO-UHFFFAOYSA-N 0.000 claims 1
• MPSVGZYAXAVLLS-UHFFFAOYSA-N 1-(4-methoxyphenyl)-4-[2-(2-methyl-5-phenyl-1H-pyrrol-3-yl)ethyl]piperazine Chemical compound COC1=CC=C(C=C1)N1CCN(CC1)CCC1=C(NC(=C1)C1=CC=CC=C1)C MPSVGZYAXAVLLS-UHFFFAOYSA-N 0.000 claims 1
• SCYLXECFODPMRZ-UHFFFAOYSA-N 1-[(2,4-dichlorophenyl)methyl]-4-[2-(2-methyl-5-phenyl-1H-pyrrol-3-yl)ethyl]piperazine Chemical compound ClC1=C(CN2CCN(CC2)CCC2=C(NC(=C2)C2=CC=CC=C2)C)C=CC(=C1)Cl SCYLXECFODPMRZ-UHFFFAOYSA-N 0.000 claims 1
• FIMOUVRDICTNRM-UHFFFAOYSA-N 1-[2-methyl-5-(oxan-4-yl)-1h-pyrrol-3-yl]-2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethane-1,2-dione Chemical compound CC=1NC(C2CCOCC2)=CC=1C(=O)C(=O)N(CC1)CCN1C1=CC=CC(C(F)(F)F)=C1 FIMOUVRDICTNRM-UHFFFAOYSA-N 0.000 claims 1
• ATPALYQUTULJLB-UHFFFAOYSA-N 1-[4-(1h-indol-4-yl)piperazin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound C=1C(C(=O)C(=O)N2CCN(CC2)C=2C=3C=CNC=3C=CC=2)=C(C)NC=1C1=CC=CC=C1 ATPALYQUTULJLB-UHFFFAOYSA-N 0.000 claims 1
• KLPDMVLSUAIIRE-UHFFFAOYSA-N 1-[4-(3,4-dichlorophenyl)piperazin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCN1C1=CC=C(Cl)C(Cl)=C1 KLPDMVLSUAIIRE-UHFFFAOYSA-N 0.000 claims 1
• ZZRFSSQFYYLVQE-UHFFFAOYSA-N 1-[4-(3,5-dichlorophenyl)piperazin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCN1C1=CC(Cl)=CC(Cl)=C1 ZZRFSSQFYYLVQE-UHFFFAOYSA-N 0.000 claims 1
• REYXRTVYVHRUSJ-UHFFFAOYSA-N 1-[4-(3-bromophenyl)piperazin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCN1C1=CC=CC(Br)=C1 REYXRTVYVHRUSJ-UHFFFAOYSA-N 0.000 claims 1
• WANGDVKXSFGBEX-UHFFFAOYSA-N 1-[4-(3-bromophenyl)piperidin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCC1C1=CC=CC(Br)=C1 WANGDVKXSFGBEX-UHFFFAOYSA-N 0.000 claims 1
• SUZCLKIKSUNRFV-UHFFFAOYSA-N 1-[4-(3-chlorophenyl)piperazin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCN1C1=CC=CC(Cl)=C1 SUZCLKIKSUNRFV-UHFFFAOYSA-N 0.000 claims 1
• ITQDKALCZQOFMT-UHFFFAOYSA-N 1-[4-(3-methoxyphenyl)piperidin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound COC1=CC=CC(C2CCN(CC2)C(=O)C(=O)C2=C(NC(=C2)C=2C=CC=CC=2)C)=C1 ITQDKALCZQOFMT-UHFFFAOYSA-N 0.000 claims 1
• JPJOKBAVRHNHKE-UHFFFAOYSA-N 1-[4-(3-methylphenyl)piperazin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCN1C1=CC=CC(C)=C1 JPJOKBAVRHNHKE-UHFFFAOYSA-N 0.000 claims 1
• FXKUBZWDTLVZHP-UHFFFAOYSA-N 1-[4-(3-methylphenyl)piperidin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCC1C1=CC=CC(C)=C1 FXKUBZWDTLVZHP-UHFFFAOYSA-N 0.000 claims 1
• SSBJSAHRLHDLRN-UHFFFAOYSA-N 1-[4-(4-acetylphenyl)piperazin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound C1=CC(C(=O)C)=CC=C1N1CCN(C(=O)C(=O)C2=C(NC(=C2)C=2C=CC=CC=2)C)CC1 SSBJSAHRLHDLRN-UHFFFAOYSA-N 0.000 claims 1
• KPEUFQPHJQJWCC-UHFFFAOYSA-N 1-[4-(4-bromobenzoyl)piperidin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCC1C(=O)C1=CC=C(Br)C=C1 KPEUFQPHJQJWCC-UHFFFAOYSA-N 0.000 claims 1
• JTQFVVDEFSJZBG-UHFFFAOYSA-N 1-[4-(4-chlorobenzoyl)piperidin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCC1C(=O)C1=CC=C(Cl)C=C1 JTQFVVDEFSJZBG-UHFFFAOYSA-N 0.000 claims 1
• JMNSJPGSDGNTCV-UHFFFAOYSA-N 1-[4-(4-chlorophenyl)piperazin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCN1C1=CC=C(Cl)C=C1 JMNSJPGSDGNTCV-UHFFFAOYSA-N 0.000 claims 1
• NMLCTMVFKKZMCY-UHFFFAOYSA-N 1-[4-(4-fluoro-3-nitrophenyl)piperidin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCC1C1=CC=C(F)C([N+]([O-])=O)=C1 NMLCTMVFKKZMCY-UHFFFAOYSA-N 0.000 claims 1
• XOELRIZFIHHDOL-UHFFFAOYSA-N 1-[4-(4-fluorobenzoyl)piperidin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCC1C(=O)C1=CC=C(F)C=C1 XOELRIZFIHHDOL-UHFFFAOYSA-N 0.000 claims 1
• XEERFRCULMOUHA-UHFFFAOYSA-N 1-[4-(4-methylbenzoyl)piperidin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCC1C(=O)C1=CC=C(C)C=C1 XEERFRCULMOUHA-UHFFFAOYSA-N 0.000 claims 1
• DINQHJMSMZPBLE-UHFFFAOYSA-N 1-[4-[4-chloro-3-(trifluoromethyl)phenyl]piperazin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCN1C1=CC=C(Cl)C(C(F)(F)F)=C1 DINQHJMSMZPBLE-UHFFFAOYSA-N 0.000 claims 1
• FGWFVAFNGRZYAG-UHFFFAOYSA-N 2-[3-[4-[2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)-2-oxoacetyl]piperazin-1-yl]phenoxy]acetamide Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCN1C1=CC=CC(OCC(N)=O)=C1 FGWFVAFNGRZYAG-UHFFFAOYSA-N 0.000 claims 1
• VSVXBNVVTIBISJ-UHFFFAOYSA-N 2-hydroxyimino-2-(2-methyl-5-phenyl-1H-pyrrol-3-yl)-1-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethanone Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=NO)C(=O)N(CC1)CCN1C1=CC=CC(C(F)(F)F)=C1 VSVXBNVVTIBISJ-UHFFFAOYSA-N 0.000 claims 1
• GCMSLZKMGYSHFQ-UHFFFAOYSA-N 3-[1-[2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)-2-oxoacetyl]piperidin-4-yl]benzoic acid Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCC1C1=CC=CC(C(O)=O)=C1 GCMSLZKMGYSHFQ-UHFFFAOYSA-N 0.000 claims 1
• RHIGGHYFJIMKPU-UHFFFAOYSA-N 3-[1-[2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)-2-oxoacetyl]piperidin-4-yl]benzonitrile Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCC1C1=CC=CC(C#N)=C1 RHIGGHYFJIMKPU-UHFFFAOYSA-N 0.000 claims 1
• FQUXHILSAJEUNG-UHFFFAOYSA-N 3-[4-[2-(2-methyl-5-phenyl-1H-pyrrol-3-yl)ethyl]piperazin-1-yl]phenol Chemical compound OC=1C=C(C=CC1)N1CCN(CC1)CCC1=C(NC(=C1)C1=CC=CC=C1)C FQUXHILSAJEUNG-UHFFFAOYSA-N 0.000 claims 1
• AUEQOSYUSYUTHO-UHFFFAOYSA-N 4-[2-[4-(3-chloro-4-fluorophenyl)piperazin-1-yl]-2-oxoacetyl]-n-(cyclopropylmethyl)-3,5-dimethyl-1h-pyrrole-2-carboxamide Chemical compound CC=1C(C(=O)C(=O)N2CCN(CC2)C=2C=C(Cl)C(F)=CC=2)=C(C)NC=1C(=O)NCC1CC1 AUEQOSYUSYUTHO-UHFFFAOYSA-N 0.000 claims 1
• NOGAHADFKFSIRU-UHFFFAOYSA-N 4-[2-[4-(3-chloro-4-fluorophenyl)piperazin-1-yl]-2-oxoacetyl]-n-(furan-2-ylmethyl)-3,5-dimethyl-1h-pyrrole-2-carboxamide Chemical compound CC=1C(C(=O)C(=O)N2CCN(CC2)C=2C=C(Cl)C(F)=CC=2)=C(C)NC=1C(=O)NCC1=CC=CO1 NOGAHADFKFSIRU-UHFFFAOYSA-N 0.000 claims 1
• PRRQVBKOSMOAAX-UHFFFAOYSA-N 4-[2-[4-(3-chlorophenyl)piperazin-1-yl]-2-oxoacetyl]-n-(cyclopropylmethyl)-3,5-dimethyl-1h-pyrrole-2-carboxamide Chemical compound CC=1C(C(=O)C(=O)N2CCN(CC2)C=2C=C(Cl)C=CC=2)=C(C)NC=1C(=O)NCC1CC1 PRRQVBKOSMOAAX-UHFFFAOYSA-N 0.000 claims 1
• TXHVZLJLYTWIMZ-UHFFFAOYSA-N 4-[2-[4-(3-chlorophenyl)piperazin-1-yl]-2-oxoacetyl]-n-(furan-2-ylmethyl)-3,5-dimethyl-1h-pyrrole-2-carboxamide Chemical compound CC=1C(C(=O)C(=O)N2CCN(CC2)C=2C=C(Cl)C=CC=2)=C(C)NC=1C(=O)NCC1=CC=CO1 TXHVZLJLYTWIMZ-UHFFFAOYSA-N 0.000 claims 1
• XGZOBGGIKSJSGS-UHFFFAOYSA-N 4-[2-[4-[4-chloro-3-(trifluoromethyl)phenyl]piperazin-1-yl]-2-oxoacetyl]-3,5-dimethyl-n-(pyridin-3-ylmethyl)-1h-pyrrole-2-carboxamide Chemical compound CC=1C(C(=O)C(=O)N2CCN(CC2)C=2C=C(C(Cl)=CC=2)C(F)(F)F)=C(C)NC=1C(=O)NCC1=CC=CN=C1 XGZOBGGIKSJSGS-UHFFFAOYSA-N 0.000 claims 1
• MQNKZNZKEFYWOL-UHFFFAOYSA-N 4-[2-[4-[4-chloro-3-(trifluoromethyl)phenyl]piperazin-1-yl]-2-oxoacetyl]-3,5-dimethyl-n-propyl-1h-pyrrole-2-carboxamide Chemical compound CC1=C(C(=O)NCCC)NC(C)=C1C(=O)C(=O)N1CCN(C=2C=C(C(Cl)=CC=2)C(F)(F)F)CC1 MQNKZNZKEFYWOL-UHFFFAOYSA-N 0.000 claims 1
• JXFYEBDPEKDIRK-UHFFFAOYSA-N 4-[2-[4-[4-chloro-3-(trifluoromethyl)phenyl]piperazin-1-yl]-2-oxoacetyl]-n-(furan-2-ylmethyl)-3,5-dimethyl-1h-pyrrole-2-carboxamide Chemical compound CC=1C(C(=O)C(=O)N2CCN(CC2)C=2C=C(C(Cl)=CC=2)C(F)(F)F)=C(C)NC=1C(=O)NCC1=CC=CO1 JXFYEBDPEKDIRK-UHFFFAOYSA-N 0.000 claims 1
• 229940125773 compound 10 Drugs 0.000 claims 1
• HWDVTQAXQJQROO-UHFFFAOYSA-N cyclopropylazanide Chemical compound [NH-]C1CC1 HWDVTQAXQJQROO-UHFFFAOYSA-N 0.000 claims 1
• 229960003850 dabigatran Drugs 0.000 claims 1
• YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 claims 1
• 229960004969 dalteparin Drugs 0.000 claims 1
• XIJGCBHXJWARSO-UHFFFAOYSA-N ethyl 2-[3-[4-[2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)-2-oxoacetyl]piperazin-1-yl]phenoxy]acetate Chemical compound CCOC(=O)COC1=CC=CC(N2CCN(CC2)C(=O)C(=O)C2=C(NC(=C2)C=2C=CC=CC=2)C)=C1 XIJGCBHXJWARSO-UHFFFAOYSA-N 0.000 claims 1
• SYMGZJFJDQPKIF-UHFFFAOYSA-N ethyl 3-[4-[2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)-2-oxoacetyl]piperazin-1-yl]benzoate Chemical compound CCOC(=O)C1=CC=CC(N2CCN(CC2)C(=O)C(=O)C2=C(NC(=C2)C=2C=CC=CC=2)C)=C1 SYMGZJFJDQPKIF-UHFFFAOYSA-N 0.000 claims 1
• ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 claims 1
• OWIHJSQJQOUXQW-UHFFFAOYSA-N n-(furan-2-ylmethyl)-3,5-dimethyl-4-[2-oxo-2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]acetyl]-1h-pyrrole-2-carboxamide Chemical compound CC=1C(C(=O)C(=O)N2CCN(CC2)C=2C=C(C=CC=2)C(F)(F)F)=C(C)NC=1C(=O)NCC1=CC=CO1 OWIHJSQJQOUXQW-UHFFFAOYSA-N 0.000 claims 1
• 239000008194 pharmaceutical composition Substances 0.000 claims 1
• LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
• 102100037600 P2Y purinoceptor 1 Human genes 0.000 abstract description 19
• 230000005764 inhibitory process Effects 0.000 abstract description 18
• 230000004913 activation Effects 0.000 abstract description 12
• 239000000825 pharmaceutical preparation Substances 0.000 abstract description 11
• 108010085249 Purinergic P2 Receptors Proteins 0.000 abstract description 6
• 208000024172 Cardiovascular disease Diseases 0.000 abstract description 4
• 230000002265 prevention Effects 0.000 abstract description 4
• 230000002744 anti-aggregatory effect Effects 0.000 abstract description 3
• 230000002785 anti-thrombosis Effects 0.000 abstract description 3
• 230000002441 reversible effect Effects 0.000 abstract description 2
• 210000001772 blood platelet Anatomy 0.000 description 40
• XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 22
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
• 239000000243 solution Substances 0.000 description 21
• 239000002253 acid Substances 0.000 description 15
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
• 239000000651 prodrug Substances 0.000 description 14
• 229940002612 prodrug Drugs 0.000 description 14
• 208000010110 spontaneous platelet aggregation Diseases 0.000 description 14
• 230000000694 effects Effects 0.000 description 13
• 102000005962 receptors Human genes 0.000 description 13
• 108020003175 receptors Proteins 0.000 description 13
• 238000003556 assay Methods 0.000 description 12
• 210000004623 platelet-rich plasma Anatomy 0.000 description 12
• 230000002776 aggregation Effects 0.000 description 11
• 238000004220 aggregation Methods 0.000 description 11
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
• 108050008996 P2Y purinoceptor 1 Proteins 0.000 description 9
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
• 210000004369 blood Anatomy 0.000 description 9
• 239000008280 blood Substances 0.000 description 9
• 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 9
• 239000002904 solvent Substances 0.000 description 9
• 230000027455 binding Effects 0.000 description 8
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
• 230000001413 cellular effect Effects 0.000 description 6
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
• 239000010410 layer Substances 0.000 description 6
• 239000012044 organic layer Substances 0.000 description 6
• 238000003786 synthesis reaction Methods 0.000 description 6
• 238000012360 testing method Methods 0.000 description 6
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
• FPQVGDGSRVMNMR-JCTPKUEWSA-N [[(z)-(1-cyano-2-ethoxy-2-oxoethylidene)amino]oxy-(dimethylamino)methylidene]-dimethylazanium;tetrafluoroborate Chemical compound F[B-](F)(F)F.CCOC(=O)C(\C#N)=N/OC(N(C)C)=[N+](C)C FPQVGDGSRVMNMR-JCTPKUEWSA-N 0.000 description 5
• 125000003277 amino group Chemical group 0.000 description 5
• 239000007864 aqueous solution Substances 0.000 description 5
• 238000006243 chemical reaction Methods 0.000 description 5
• 238000004128 high performance liquid chromatography Methods 0.000 description 5
• 239000011541 reaction mixture Substances 0.000 description 5
• 238000003756 stirring Methods 0.000 description 5
• 239000000126 substance Substances 0.000 description 5
• 239000003826 tablet Substances 0.000 description 5
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
• 101001120086 Homo sapiens P2Y purinoceptor 12 Proteins 0.000 description 4
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
• JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
• 150000001450 anions Chemical class 0.000 description 4
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
• 239000000969 carrier Substances 0.000 description 4
• 201000010099 disease Diseases 0.000 description 4
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
• CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
• 239000008188 pellet Substances 0.000 description 4
• 230000010118 platelet activation Effects 0.000 description 4
• 238000000159 protein binding assay Methods 0.000 description 4
• 239000011780 sodium chloride Substances 0.000 description 4
• 239000007858 starting material Substances 0.000 description 4
• 238000006467 substitution reaction Methods 0.000 description 4
• LOLZVJJIBIGCFD-UHFFFAOYSA-N 2-methyl-5-phenyl-1h-pyrrole Chemical compound N1C(C)=CC=C1C1=CC=CC=C1 LOLZVJJIBIGCFD-UHFFFAOYSA-N 0.000 description 3
• XQGVQRPSTODODM-UHFFFAOYSA-N 3,5-dimethyl-1h-pyrrole-2-carboxylic acid Chemical compound CC1=CC(C)=C(C(O)=O)N1 XQGVQRPSTODODM-UHFFFAOYSA-N 0.000 description 3
• VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 3
• HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 3
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
• ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 3
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
• 239000001828 Gelatine Substances 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
• 108091007960 PI3Ks Proteins 0.000 description 3
• 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 3
• 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 3
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
• 238000002835 absorbance Methods 0.000 description 3
• 235000011054 acetic acid Nutrition 0.000 description 3
• 239000001099 ammonium carbonate Substances 0.000 description 3
• 235000012501 ammonium carbonate Nutrition 0.000 description 3
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
• 229910052794 bromium Inorganic materials 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• 239000002775 capsule Substances 0.000 description 3
• 210000004027 cell Anatomy 0.000 description 3
• 210000000170 cell membrane Anatomy 0.000 description 3
• 239000003795 chemical substances by application Substances 0.000 description 3
• 238000004587 chromatography analysis Methods 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• IMOGKALIAJTGCX-UHFFFAOYSA-N ethyl 3,5-dimethyl-4-[2-oxo-2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]acetyl]-1h-pyrrole-2-carboxylate Chemical compound CC1=C(C(=O)OCC)NC(C)=C1C(=O)C(=O)N1CCN(C=2C=C(C=CC=2)C(F)(F)F)CC1 IMOGKALIAJTGCX-UHFFFAOYSA-N 0.000 description 3
• 125000000524 functional group Chemical group 0.000 description 3
• 229920000159 gelatin Polymers 0.000 description 3
• 235000019322 gelatine Nutrition 0.000 description 3
• 238000001727 in vivo Methods 0.000 description 3
• 239000003112 inhibitor Substances 0.000 description 3
• 239000000543 intermediate Substances 0.000 description 3
• 239000012528 membrane Substances 0.000 description 3
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
• 210000002381 plasma Anatomy 0.000 description 3
• 230000018127 platelet degranulation Effects 0.000 description 3
• 125000006239 protecting group Chemical group 0.000 description 3
• 239000000523 sample Substances 0.000 description 3
• 125000001424 substituent group Chemical group 0.000 description 3
• 230000001732 thrombotic effect Effects 0.000 description 3
• 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
• KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
• JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 2
• KKIMDKMETPPURN-UHFFFAOYSA-N 1-(3-(trifluoromethyl)phenyl)piperazine Chemical compound FC(F)(F)C1=CC=CC(N2CCNCC2)=C1 KKIMDKMETPPURN-UHFFFAOYSA-N 0.000 description 2
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
• 239000005711 Benzoic acid Substances 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
• 102000008186 Collagen Human genes 0.000 description 2
• 108010035532 Collagen Proteins 0.000 description 2
• QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
• ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
• QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
• 239000007995 HEPES buffer Substances 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
• BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
• 229940127424 P2Y12 Receptor Antagonists Drugs 0.000 description 2
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
• KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 239000004743 Polypropylene Substances 0.000 description 2
• 108090000190 Thrombin Proteins 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 239000000654 additive Substances 0.000 description 2
• 102000030621 adenylate cyclase Human genes 0.000 description 2
• 108060000200 adenylate cyclase Proteins 0.000 description 2
• 239000000443 aerosol Substances 0.000 description 2
• 229910021529 ammonia Inorganic materials 0.000 description 2
• 239000008346 aqueous phase Substances 0.000 description 2
• 229910052786 argon Inorganic materials 0.000 description 2
• 239000012131 assay buffer Substances 0.000 description 2
• 239000002585 base Substances 0.000 description 2
• 235000010233 benzoic acid Nutrition 0.000 description 2
• 230000017531 blood circulation Effects 0.000 description 2
• 238000005119 centrifugation Methods 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 229920001436 collagen Polymers 0.000 description 2
• 239000000470 constituent Substances 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 208000035475 disorder Diseases 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 2
• MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 2
• DDRPCXLAQZKBJP-UHFFFAOYSA-N furfurylamine Chemical compound NCC1=CC=CO1 DDRPCXLAQZKBJP-UHFFFAOYSA-N 0.000 description 2
• 238000010438 heat treatment Methods 0.000 description 2
• 102000043971 human P2RY12 Human genes 0.000 description 2
• 150000002430 hydrocarbons Chemical group 0.000 description 2
• 239000007943 implant Substances 0.000 description 2
• 238000000338 in vitro Methods 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 230000028709 inflammatory response Effects 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• 230000000977 initiatory effect Effects 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• 230000003834 intracellular effect Effects 0.000 description 2
• 239000004310 lactic acid Substances 0.000 description 2
• 235000014655 lactic acid Nutrition 0.000 description 2
• QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
• 239000003094 microcapsule Substances 0.000 description 2
• 150000007522 mineralic acids Chemical class 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• 230000000269 nucleophilic effect Effects 0.000 description 2
• 230000003647 oxidation Effects 0.000 description 2
• 238000007254 oxidation reaction Methods 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• 239000006187 pill Substances 0.000 description 2
• 229920005862 polyol Polymers 0.000 description 2
• 150000003077 polyols Chemical class 0.000 description 2
• 229920001155 polypropylene Polymers 0.000 description 2
• 239000002244 precipitate Substances 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 230000002685 pulmonary effect Effects 0.000 description 2
• 230000028327 secretion Effects 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 230000006641 stabilisation Effects 0.000 description 2
• 238000011105 stabilization Methods 0.000 description 2
• 239000006228 supernatant Substances 0.000 description 2
• 239000000829 suppository Substances 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• 229960004072 thrombin Drugs 0.000 description 2
• 210000001519 tissue Anatomy 0.000 description 2
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
• 210000005166 vasculature Anatomy 0.000 description 2
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
• SIZRIGSBZPWTOL-UHFFFAOYSA-N 1,3-dimethylpyrrole-2-carboxylic acid Chemical compound CC=1C=CN(C)C=1C(O)=O SIZRIGSBZPWTOL-UHFFFAOYSA-N 0.000 description 1
• WMKGGPCROCCUDY-UHFFFAOYSA-N 1,5-diphenylpenta-1,4-dien-3-one Chemical compound C=1C=CC=CC=1C=CC(=O)C=CC1=CC=CC=C1 WMKGGPCROCCUDY-UHFFFAOYSA-N 0.000 description 1
• WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
• MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
• QUFYPJILXRCKSB-UHFFFAOYSA-N 1-ethyl-4-phenylpiperazine Chemical compound C1CN(CC)CCN1C1=CC=CC=C1 QUFYPJILXRCKSB-UHFFFAOYSA-N 0.000 description 1
• 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
• ZRBOKMCFDBJZDP-UHFFFAOYSA-N 2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)-2-oxoacetic acid Chemical compound OC(=O)C(=O)C1=C(C)NC(C=2C=CC=CC=2)=C1 ZRBOKMCFDBJZDP-UHFFFAOYSA-N 0.000 description 1
• 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
• MYVHMGNKBVYIBT-UHFFFAOYSA-N 2-oxo-1h-quinoline-3-carboxamide Chemical class C1=CC=C2NC(=O)C(C(=O)N)=CC2=C1 MYVHMGNKBVYIBT-UHFFFAOYSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• 125000005917 3-methylpentyl group Chemical group 0.000 description 1
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
• 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
• 241000114726 Acetes Species 0.000 description 1
• XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 1
• USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
• 239000005695 Ammonium acetate Substances 0.000 description 1
• 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
• 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
• 206010008088 Cerebral artery embolism Diseases 0.000 description 1
• 206010008092 Cerebral artery thrombosis Diseases 0.000 description 1
• 208000017667 Chronic Disease Diseases 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 206010011084 Coronary artery embolism Diseases 0.000 description 1
• 206010011091 Coronary artery thrombosis Diseases 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 206010014513 Embolism arterial Diseases 0.000 description 1
• 206010014522 Embolism venous Diseases 0.000 description 1
• 241000854350 Enicospilus group Species 0.000 description 1
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
• PAEYAKGINDQUCT-UHFFFAOYSA-N Ethyl 2-pyrrolecarboxylate Chemical compound CCOC(=O)C1=CC=CN1 PAEYAKGINDQUCT-UHFFFAOYSA-N 0.000 description 1
• 239000005977 Ethylene Substances 0.000 description 1
• 238000005863 Friedel-Crafts acylation reaction Methods 0.000 description 1
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 239000007821 HATU Substances 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101001098232 Homo sapiens P2Y purinoceptor 1 Proteins 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 241001465754 Metazoa Species 0.000 description 1
• RRQQUWXUIXLJGW-UHFFFAOYSA-N N-(cyclopropylmethyl)-1H-pyrrole-2-carboxamide Chemical compound C1(CC1)CNC(=O)C=1NC=CC1 RRQQUWXUIXLJGW-UHFFFAOYSA-N 0.000 description 1
• APQUQTWVYOBFLP-UHFFFAOYSA-N N-(furan-2-ylmethyl)-1,3-dimethylpyrrole-2-carboxamide Chemical compound O1C(=CC=C1)CNC(=O)C=1N(C=CC1C)C APQUQTWVYOBFLP-UHFFFAOYSA-N 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• 239000002172 P2Y12 inhibitor Substances 0.000 description 1
• 208000018262 Peripheral vascular disease Diseases 0.000 description 1
• 108010028935 Purinergic P2Y1 Receptors Proteins 0.000 description 1
• 102000016927 Purinergic P2Y1 Receptors Human genes 0.000 description 1
• 102000001744 Purinergic P2Y2 Receptors Human genes 0.000 description 1
• 108010029812 Purinergic P2Y2 Receptors Proteins 0.000 description 1
• 206010037549 Purpura Diseases 0.000 description 1
• 241001672981 Purpura Species 0.000 description 1
• 206010063544 Renal embolism Diseases 0.000 description 1
• 229910018162 SeO2 Inorganic materials 0.000 description 1
• 208000007718 Stable Angina Diseases 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 238000007296 Stetter synthesis reaction Methods 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• WLMZTKAZJUWXCB-KQYNXXCUSA-N [(2r,3s,4r,5r)-5-(6-amino-2-methylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate Chemical compound C12=NC(SC)=NC(N)=C2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O WLMZTKAZJUWXCB-KQYNXXCUSA-N 0.000 description 1
• 150000001242 acetic acid derivatives Chemical class 0.000 description 1
• 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
• PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
• WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
• 239000012346 acetyl chloride Substances 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000004931 aggregating effect Effects 0.000 description 1
• 230000008484 agonism Effects 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 235000019257 ammonium acetate Nutrition 0.000 description 1
• 229940043376 ammonium acetate Drugs 0.000 description 1
• 150000003863 ammonium salts Chemical class 0.000 description 1
• 238000005349 anion exchange Methods 0.000 description 1
• 230000003042 antagnostic effect Effects 0.000 description 1
• 230000008485 antagonism Effects 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 description 1
• 229960004676 antithrombotic agent Drugs 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 150000005840 aryl radicals Chemical class 0.000 description 1
• 230000006399 behavior Effects 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
• 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 210000000601 blood cell Anatomy 0.000 description 1
• 230000023555 blood coagulation Effects 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 239000012267 brine Substances 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 159000000007 calcium salts Chemical class 0.000 description 1
• 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
• 150000001735 carboxylic acids Chemical class 0.000 description 1
• 238000013172 carotid endarterectomy Methods 0.000 description 1
• 238000005341 cation exchange Methods 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 238000007385 chemical modification Methods 0.000 description 1
• 210000003040 circulating cell Anatomy 0.000 description 1
• 235000015165 citric acid Nutrition 0.000 description 1
• 229960003009 clopidogrel Drugs 0.000 description 1
• GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
• 230000035602 clotting Effects 0.000 description 1
• 230000015271 coagulation Effects 0.000 description 1
• 238000005345 coagulation Methods 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 238000012875 competitive assay Methods 0.000 description 1
• 238000006482 condensation reaction Methods 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 229940099112 cornstarch Drugs 0.000 description 1
• 208000002528 coronary thrombosis Diseases 0.000 description 1
• 210000004351 coronary vessel Anatomy 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• 229960000288 dabigatran etexilate Drugs 0.000 description 1
• KSGXQBZTULBEEQ-UHFFFAOYSA-N dabigatran etexilate Chemical compound C1=CC(C(N)=NC(=O)OCCCCCC)=CC=C1NCC1=NC2=CC(C(=O)N(CCC(=O)OCC)C=3N=CC=CC=3)=CC=C2N1C KSGXQBZTULBEEQ-UHFFFAOYSA-N 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
• 229960004132 diethyl ether Drugs 0.000 description 1
• VLNZUSMTOFYNPS-UHFFFAOYSA-N diethylphosphorylformonitrile Chemical compound CCP(=O)(CC)C#N VLNZUSMTOFYNPS-UHFFFAOYSA-N 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
• 239000003480 eluent Substances 0.000 description 1
• 230000010102 embolization Effects 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 210000003038 endothelium Anatomy 0.000 description 1
• ALRDOFWBPAZOCW-UHFFFAOYSA-N ethyl 4-acetyl-3,5-dimethyl-1h-pyrrole-2-carboxylate Chemical compound CCOC(=O)C=1NC(C)=C(C(C)=O)C=1C ALRDOFWBPAZOCW-UHFFFAOYSA-N 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 238000010228 ex vivo assay Methods 0.000 description 1
• 239000003925 fat Substances 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 230000020764 fibrinolysis Effects 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 235000019253 formic acid Nutrition 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 238000005462 in vivo assay Methods 0.000 description 1
• 230000004941 influx Effects 0.000 description 1
• 239000003978 infusion fluid Substances 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 238000003780 insertion Methods 0.000 description 1
• 230000037431 insertion Effects 0.000 description 1
• 230000031146 intracellular signal transduction Effects 0.000 description 1
• 201000010849 intracranial embolism Diseases 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 230000002427 irreversible effect Effects 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 159000000003 magnesium salts Chemical class 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 239000001630 malic acid Substances 0.000 description 1
• 235000011090 malic acid Nutrition 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
• ZOJVWKPLKZVSLQ-UHFFFAOYSA-N n-cyclopropyl-1h-pyrrole-2-carboxamide Chemical compound C=1C=CNC=1C(=O)NC1CC1 ZOJVWKPLKZVSLQ-UHFFFAOYSA-N 0.000 description 1
• WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 230000010807 negative regulation of binding Effects 0.000 description 1
• 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
• 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 239000012074 organic phase Substances 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• 150000002923 oximes Chemical class 0.000 description 1
• 229910052763 palladium Inorganic materials 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 239000012071 phase Substances 0.000 description 1
• 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
• UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
• 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 159000000001 potassium salts Chemical class 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 201000011461 pre-eclampsia Diseases 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
• 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
• 239000000719 purinergic P2Y receptor antagonist Substances 0.000 description 1
• HDOUGSFASVGDCS-UHFFFAOYSA-N pyridin-3-ylmethanamine Chemical compound NCC1=CC=CN=C1 HDOUGSFASVGDCS-UHFFFAOYSA-N 0.000 description 1
• DOYOPBSXEIZLRE-UHFFFAOYSA-N pyrrole-3-carboxylic acid Natural products OC(=O)C=1C=CNC=1 DOYOPBSXEIZLRE-UHFFFAOYSA-N 0.000 description 1
• 150000007660 quinolones Chemical class 0.000 description 1
• 239000000018 receptor agonist Substances 0.000 description 1
• 229940044601 receptor agonist Drugs 0.000 description 1
• 238000003259 recombinant expression Methods 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 1
• 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 1
• 238000007086 side reaction Methods 0.000 description 1
• 159000000000 sodium salts Chemical class 0.000 description 1
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
• 230000009870 specific binding Effects 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 230000000707 stereoselective effect Effects 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 150000003460 sulfonic acids Chemical class 0.000 description 1
• 238000006557 surface reaction Methods 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 239000012622 synthetic inhibitor Substances 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
• WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
• QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
• 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
• WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
• 125000001113 thiadiazolyl group Chemical group 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 239000002175 thienopyridine Substances 0.000 description 1
• 229940125670 thienopyridine Drugs 0.000 description 1
• 201000005060 thrombophlebitis Diseases 0.000 description 1
• 229960005001 ticlopidine Drugs 0.000 description 1
• PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
• 125000004306 triazinyl group Chemical group 0.000 description 1
• 125000001425 triazolyl group Chemical group 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 1
• DYNGCIHMNWOBSU-MSQVLRTGSA-K trisodium;[[(2r,3s,4r,5r)-5-(6-amino-2-methylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] phosphate Chemical compound [Na+].[Na+].[Na+].C12=NC(SC)=NC(N)=C2N=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O DYNGCIHMNWOBSU-MSQVLRTGSA-K 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 208000004043 venous thromboembolism Diseases 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 238000005303 weighing Methods 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 238000010626 work up procedure Methods 0.000 description 1